SCHEMBL4707591

SCHEMBL4707591

O=C(OC1CCCN(c2ccc(F)cc2F)C1)N1C2CCC1CC(O)C2

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACACB O00763 3/20 0.41
DPP4 P27487 1/20 0.38
DPP8 Q6V1X1 1/20 0.38
DPP9 Q86TI2 1/20 0.38
DPP7 Q9UHL4 1/20 0.38
KDM4E B2RXH2 2/20 0.36
HTT P42858 1/20 0.36
HRH3 Q9Y5N1 2/20 0.35
GPR119 Q8TDV5 1/20 0.35
CHRM2 P08172 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
LIPG Q9Y5X9 2/20 0.34
GRM5 P41594 1/20 0.34
LIPC P11150 1/20 0.34
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5661324 0.97 ACACB (0.41) ACACBDPP4DPP8DPP9DPP7
SCHEMBL5662757 0.90 CHEK1 (0.34) ACACBDPP4DPP8DPP9DPP7
SCHEMBL5664969 0.90 GAA (0.40) ACACBDPP4DPP8DPP9DPP7
SCHEMBL4817742 0.90 ACACB (0.44) ACACBGPR119CHRM2CHRM1CHRM3
SCHEMBL5662027 0.87 NOTUM (0.44) HTTGPR119MEN1ALDH1A1KMT2A
SCHEMBL5663752 0.87 SLC6A9 (0.42) DPP4DPP8DPP9DPP7GPR119
SCHEMBL4759493 0.87 ACACB (0.43) ACACBHRH3GPR119ALDH1A1
SCHEMBL5661789 0.87 ACACB (0.41) ACACBDPP4DPP8DPP9DPP7
SCHEMBL14436814 0.87 ACACB (0.41) ACACBDPP4DPP8DPP9DPP7
SCHEMBL5662929 0.86 ALDH1A1 (0.48) DPP4HTTALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979318-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2008-10-15 EP claimed
US-20070197530-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-08-23 US claimed
WO-2007089683-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2007-08-09 WO claimed
US-20070197530-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-08-23 US disclosed
US-20070197530-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-08-23 US disclosed
US-20070197530-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197530-A1 Amido compounds and their use as pharmaceuticals HSD11B1, HSD17B11, CYP11B1 ACACB 395/4885DPP4 2060/4885DPP8 2197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.